Literature DB >> 22043363

Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report.

Ali M Al-Amri1.   

Abstract

Planning for treatment of gastric adenocarcinoma in a patient previously treated with partial gastrectomy for primary gastric lymphoma is difficult. Long term survival of advanced gastric adenocarcinoma is poor with therapy and even worse without treatment. The only potentially curative treatment for gastric adenocarcinoma is surgical resection with adequate margins. Palliative surgery ameliorate symptoms in about 50% of patients Chemotherapy may play a lesser role. This report presents a case of gastric adenocarcinoma in a patient who had primary gastric lymphoma treated with partial gastrectomy. The patient is still alive 6 years after diagnosis with no signs of progression despite the fact that no active treatment was given.

Entities:  

Year:  2010        PMID: 22043363      PMCID: PMC3191651          DOI: 10.5001/omj.2010.87

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  13 in total

1.  Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.

Authors:  Motoki Yoshida; Atsushi Ohtsu; Narikazu Boku; Yoshinori Miyata; Kuniaki Shirao; Yasuhiro Shimada; Ichinosuke Hyodo; Wasaburo Koizumi; Minoru Kurihara; Shigeaki Yoshida; Seiichiro Yamamoto
Journal:  Jpn J Clin Oncol       Date:  2004-11       Impact factor: 3.019

Review 2.  Evolving chemotherapy for advanced gastric cancer.

Authors:  Jaffer A Ajani
Journal:  Oncologist       Date:  2005

Review 3.  Gastric adenocarcinoma.

Authors:  B J Dupont; I Cohn
Journal:  Curr Probl Cancer       Date:  1980-02       Impact factor: 3.187

4.  Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution.

Authors:  Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick
Journal:  J Gastrointest Surg       Date:  2005 May-Jun       Impact factor: 3.452

5.  The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis.

Authors:  S A Hundahl; J L Phillips; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

6.  The natural history of gastric cancer and prognostic factors influencing survival.

Authors:  A Y Bedikian; T T Chen; N Khankhanian; L K Heilbrun; C M McBride; M J McMurtrey; G P Bodey
Journal:  J Clin Oncol       Date:  1984-04       Impact factor: 44.544

7.  Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan.

Authors:  W J Lee; W C Lee; S J Houng; C T Shun; R L Houng; P H Lee; K J Chang; T C Wei; K M Chen
Journal:  World J Surg       Date:  1995 Sep-Oct       Impact factor: 3.352

8.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.

Authors:  J S Waters; A Norman; D Cunningham; J H Scarffe; A Webb; P Harper; J K Joffe; M Mackean; J Mansi; M Leahy; A Hill; J Oates; S Rao; M Nicolson; T Hickish
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Gastric carcinoma: review of the results of treatment in a community teaching hospital.

Authors:  Vincent H Heemskerk; Fanneke Lentze; Karel W E Hulsewé; Ton G M Hoofwijk
Journal:  World J Surg Oncol       Date:  2007-07-20       Impact factor: 2.754

10.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  2 in total

1.  Primary Gastric Chorioadenocarcinoma.

Authors:  Bahaaeldin A Baraka; Suad S Al Kharusi; Bassim J Al Bahrani; Gunmala Bhathagar
Journal:  Oman Med J       Date:  2016-09

2.  MIIP is downregulated in gastric cancer and its forced expression inhibits proliferation and invasion of gastric cancer cells in vitro and in vivo.

Authors:  Dan Sun; Yiwei Wang; Shanshan Jiang; Gang Wang; Yan Xin
Journal:  Onco Targets Ther       Date:  2018-12-11       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.